CPA CGA - NeonMind Biosciences Chief Officer
| NMDBFDelisted Stock | USD 0.50 0.00 0.00% |
Insider
CPA CGA is Chief Officer of NeonMind Biosciences
| Age | 53 |
| Phone | 866 811 8960 |
| Web | https://www.neonmindbiosciences.com |
NeonMind Biosciences Management Efficiency
The company has return on total asset (ROA) of (1.8822) % which means that it has lost $1.8822 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (37.2157) %, meaning that it generated substantial loss on money invested by shareholders. NeonMind Biosciences' management efficiency ratios could be used to measure how well NeonMind Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.NeonMind Biosciences has accumulated 450.01 K in total debt with debt to equity ratio (D/E) of 1.58, which is about average as compared to similar companies. NeonMind Biosciences has a current ratio of 0.58, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist NeonMind Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, NeonMind Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like NeonMind Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for NeonMind to invest in growth at high rates of return. When we think about NeonMind Biosciences' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Thomas Schaible | Fortress Biotech | N/A | |
| Prof MD | Hookipa Pharma | 80 | |
| Robert Barrow | Mind Medicine | 35 | |
| John Kanakis | Cybin Inc | 43 | |
| Paul Glavine | Cybin Inc | 35 | |
| Mike Preigh | Day One Biopharmaceuticals | N/A | |
| Weidong Zhong | Terns Pharmaceuticals | 58 | |
| Julie MBA | Day One Biopharmaceuticals | 42 | |
| Christine MBA | Hookipa Pharma | 59 | |
| Florian M | GH Research PLC | 55 | |
| Mark Vignola | Terns Pharmaceuticals | 46 | |
| Florian Brand | ATAI Life Sciences | 37 | |
| Senthil Sundaram | Terns Pharmaceuticals | 46 | |
| Lukas Flatz | Hookipa Pharma | N/A | |
| Madison Crawford | ATAI Life Sciences | N/A | |
| Aaqil Anwar | ATAI Life Sciences | N/A | |
| Scott MD | Mind Medicine | 67 | |
| Marine Popoff | Hookipa Pharma | N/A | |
| Arthur Taveras | X4 Pharmaceuticals | 60 | |
| Greg Cavers | Cybin Inc | 53 | |
| Julie ACA | GH Research PLC | 38 | |
Management Performance
| Return On Equity | -37.22 | |||
| Return On Asset | -1.88 |
NeonMind Biosciences Leadership Team
Elected by the shareholders, the NeonMind Biosciences' board of directors comprises two types of representatives: NeonMind Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NeonMind. The board's role is to monitor NeonMind Biosciences' management team and ensure that shareholders' interests are well served. NeonMind Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NeonMind Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA BA, CEO CoFounder | ||
| Tamara Melck, Chief Officer | ||
| Robert Tessarolo, Pres Chairman | ||
| Ernie Ho, VP Devel | ||
| CPA CGA, Chief Officer | ||
| Trevor Millar, Advisor |
NeonMind Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is NeonMind Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -37.22 | |||
| Return On Asset | -1.88 | |||
| Operating Margin | 735.17 % | |||
| Current Valuation | 799.08 K | |||
| Shares Outstanding | 35.82 M | |||
| Price To Book | 12.19 X | |||
| Price To Sales | 18.10 X | |||
| Gross Profit | (84.45 K) | |||
| EBITDA | (6.65 M) | |||
| Net Income | (7.21 M) |
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in NeonMind Pink Sheet
If you are still planning to invest in NeonMind Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NeonMind Biosciences' history and understand the potential risks before investing.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |